|
|
|
There has been a remarkable decline in cardiovascular mortality over the last two decades and a revolution in revascularization strategies, where percutaneous revascularization has replaced many surgical interventions. Breakthrough innovations in non-surgical treatment, including stent technologies and drug eluting stents, have made major contributions to this field.
|
|
|
|
|
|
Rambam's clinical scientists have been trailblazers in these important developments, including innovations in coronary stent technology, intra-cardiac navigational and electrophysiological mapping for treatment of arrhythmias, and other related discoveries. In a synergistic merging of the engineering and clinical sciences, Rambam cardiologists have teamed up with biomedical engineers to introduce life-saving technologies to clinical practice and taught their use internationally. Imaging, computer simulation and intracardiac navigation, regenerative cardiology using stem cell technology, and advanced pharmacogenetics to enable personalized therapy have all been strong components of the cardiovascular program.
The cardiovascular activity at Rambam and the Technion's Faculties of Medicine and Biomedical Engineering has generated premiere international leadership. Professor Beyar, the current Director-General and CEO of Rambam, and a pioneer in cardiovascular science and biomedical engineering, served as Dean of the Rappaport Faculty of Medicine for six years. During his tenure as Dean, Professor Beyar established a prestigious collaboration program in biomedical science and engineering between Johns Hopkins Hospital and the Technion, with a strong focus in Cardiovascular Medicine and Science, as well as the Cardiovascular Center within the Rappaport Institute for Research in the Medical Sciences.
|
|
|
|
|
|
|
|
|
| Main Link
: |
| Link Title: |
|
| Url: |
|
|
Choose existing Posting
|
|
Choose From Resource Gallery
|
|
|
|
|
|
|
|